Fatal adverse events - Open Access .click

Results 211 to 220 of about 113,942 (235)

Some of the next articles are maybe not open access.

Life-Threatening and Fatal Adverse Drug Events in a Danish University Hospital

Journal of Patient Safety, 2017
Objectives Detection of adverse drug events (ADEs) in Danish hospitals relies on health care professionals’ incident reporting to a national database for adverse events, but the method is incomplete; thus, fatal and life-threatening ADEs may remain unrecognized.
Tchijevitch, Olga A +2 more
openaire +2 more sources

Adverse event analysis in fatal cases of influenza A (H1N1) – A lesson from Poland

Journal of Forensic and Legal Medicine, 2013
During pandemic of influenza A (H1N1) in 2009 the relationship between mortality and medical errors, especially delayed antiviral treatment initiation, was highlighted in many studies. Our study was based on 5 fatal cases of pandemic influenza A (H1N1) hospitalized in Poland between November 2009 and February 2011.
Tomasz, Jurek, Marta, Rorat
openaire +3 more sources

Fatal and Adverse Events from Acupuncture: Allegation, Evidence, and the Implications

The Journal of Alternative and Complementary Medicine, 1999
In response to recent reviews in the literature that have focused on adverse events due to acupuncture treatment, this article reexamines the original reports from which they derive, particularly the fatalities allegedly caused by acupuncture. The article explores some important issues relating to the debate on risk and safety.
openaire +2 more sources

The epidemiology of fatalities reported to the Vaccine Adverse Event Reporting System 1990–1997

Pharmacoepidemiology and Drug Safety, 2001
AbstractPurposeTo examine the fatalities reported to the federally administered Vaccine Adverse Event Reporting System (VAERS), a passive surveillance system, in its first 7 years.MethodsThe working data set included variables such as demographic information, dates of vaccination, adverse event onset and death, vaccines administered, and vaccination ...
L E, Silvers +5 more
openaire +2 more sources

Abstract WP73: Potentially Fatal Adverse Allergic Events to Intravenous Thrombolytics: An analysis from Adverse Event Reporting System

Stroke, 2013
Objective: Adverse events including intracerebral hemorrhage (ICH) and reperfusion arrythmias are known to occur with thrombolytic therapy. Due to limited data, our goal is to describe the types of allergic adverse events directly attributable to IV thrombolytics. Methods:
Asif A Khan +3 more
openaire +1 more source

Investigational New Drugs, 2017
Regorafenib (Stivarga) is an oral small-molecule multikinase inhibitor commonly used against a variety of cancers. We performed a meta-analysis of all phase 3 randomized controlled trials (RCTs) of regorafenib to quantify the increased risk of SAEs and FAEs. We carried out a systematic search of electronic databases for studies published from inception
Meihui Cao, Feifei Li, Yue Wang, Jingdong Zhang +3 more
openaire +2 more sources

Fatal adverse events during hospital stays.

Prescrire international, 2011
A study of the frequency and severity of adverse events during hospital stays, based on a sample of US Medicare beneficiaries, was published in late 2010. Medicare provides healthcare coverage for people aged 65 and over, the disabled, and patients with renal impairment.
openaire +1 more source

Fatal Cisplatin Overdose in the Treatment of Mediastinal Lymphoma with the ESHAP Regimen – Analysis of the Causes of the Adverse Drug Event

Oncology Research and Treatment, 2013
Background: Cisplatin is a chemotherapeutic agent that may cause acute (or chronic) organ toxicity. As there is no antidote, prevention of adverse drug events is essential for patients’ safety. Case Report: The authors present the case of a 33-year-old woman treated for ...
Tomasz, Jurek +3 more
openaire +2 more sources

Fatal adverse event secondary to high osmolality contrast agent.

Veterinary and human toxicology, 1998
Adverse drug events secondary to iodinated contrast agents are of particular concern to all clinicians. Despite the availability of newer agents, the mortality rates remain unchanged. We describe a fatal adverse event secondary to use of the high osmolality agent iothalmate meglumine 30%.
R, Guharoy, J, Medicis, D, Lehmann
openaire +1 more source

Risk of fatal adverse events with bevacizumab in cancer patients treated with chemotherapy: A meta-analysis.

Journal of Clinical Oncology, 2010
e19500 Background: Bevacizumab has been used extensively in the treatment of advanced cancer in combination with chemotherapy.
S. Hapani, V. Ranpura, S. Wu
openaire +1 more source

3. good health
humans
female

male
adult
drug-related side effects and adverse reactions

adverse drug reaction reporting systems
aged
neoplasms